BIOA B — BioArctic AB (publ) Share News
0.000.00%
Last trade - 00:00- SEK26.00bn
- SEK24.10bn
- SEK2.00bn
Brief: BioArctic Says Leqembi Subcutaneous Formulation Approved For Initiation Treatment In China
Brief: BioArctic Says Canada's Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement Of Leqembi
Sweden's BioArctic Q2 revenue falls despite higher Leqembi royalties
Brief: BioArctic Q2 Net Sales Down At SEK 247.5 Mln
Brief: BioArctic Q2 Operating Profit SEK -6.5 Million
Brief: Bioarctic, Mesenkia Enter Oncology Research Collaboration
Brief: Bioarctic Says 29.3 Bln Yen In Q2 Sales Of Leqembi®
Brief: BioArctic Says Eisai Presented New Leqembi Data
Brief: BioArctic And Lilly Sign Research, Collaboration Agreement
Brief: Bioarctic AB Declares Dividend Of Sek 2 Per Share With 1 June 2026 Record Date
Brief: Bioarctic Partner Eisai Presents Leqembi Sales Simulation
Sweden's BioArctic Q1 revenue drops sharply despite higher Leqembi royalties
Brief: BioArctic Q1 Operating Profit SEK 210.8 Million
Brief: BioArctic: Leqembi To Generate About SEK 880 Million In Royalty
Sweden's BioArctic Q4 revenue rises 82% on Leqembi royalties
Brief: Bioarctic Proposes Dividend Of 2.00 Sek Per Share For 2025
Brief: BioArctic Reports Q4 Sales Of Leqembi At SEK 20.7 Billion
Brief: Eisai submits Marketing Authorisation Variation to EMA
Brief: Eisai Submits Marketing Authorisation Variation To EMA For Intravenous Maintenance Dosing With Leqembi